1 Result: Ipsen
Momentum Surge: Elafibranor's PBC Trial Data Boosts Genfit
June 30th, 2023
Ipsen S.A. (OTCMKTS: IPSEY) and Genfit S.A. (Nasdaq: GNFT) have announced positive results from the ELATIVE Phase III trial evaluating elafibranor as a treatment for patients with primary biliary cholangitis (PBC), a rare cholestatic liver disease, w. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login